Načítá se...
CFTR potentiators: From Bench to Bedside
One major breakthrough in cystic fibrosis research in the past decade is the development of drugs that target the root cause of the disease—dysfunctional CFTR protein. One of the compounds, Ivacaftor or Kalydeco, which has been approved for clinical use since 2012, acts by promoting the gating funct...
Uloženo v:
| Vydáno v: | Curr Opin Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5723237/ https://ncbi.nlm.nih.gov/pubmed/29073476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coph.2017.09.015 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|